Document is current

Article History

Received: 25 August 2020

Accepted: 12 March 2021

First Online: 7 May 2021

Declarations

:

: The protocol, the informed consent from (ICF) and all forms of participant information related to the study have been reviewed and approved by the UCLA institutional review board (UCLA IRB#20–000378). Any changes made to the protocol will be submitted as a modification and will be approved by the IRB prior to implementation.All subjects must sign and personally date the IRB approved ICF after receiving detailed written and verbal information about the reason, the nature and the details of the trial prior to the initiation of any study-related procedures. Patients will be informed of the extent to which their confidential health information generated from this study may be used for research and publication purposes. This will be done according to the guidelines provided in the Declaration of Helsinki, ICH E6 Guideline for Good Clinical Practice (GCP) and government regulations, including (as applicable) the US Code of Federal Regulations Title 21 CFR 50.20 through 50.27. The protocol, the ICF and all forms of participant information related to the study are currently being reviewed by the Essen institutional review board.

: Patients will be informed of the extent to which their confidential health information generated from this study may be used for research and publication purposes.

: JCa reports prior consulting activities outside of the submitted work for Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen, Progenics, Radiomedix and Telix pharmaceuticals.SZ was a consultant for ABX and Sofie Biosciences, outside of the submitted work.ME was a consultant for ABX, Blue Earth Diagnostics and Progenics and has patent rights on rhPSMA, outside of the submitted work.BH reports personal fees from ABX, Bayer, Lightpoint Medical, Inc., Janssen R&D, Bristol-Myers-Squibb and Astellas and travel from AstraZeneca, Janssen R&D and Astellas.KH is a board member, and holds equity in Sofie Biosciences. Intellectual property is patented by the University of California and licensed to Sofie Biosciences. KHe was a consultant for Advanced Accelerator Applications, Amgen, Bayer, Curium Pharma, GE Healthcare, IPSEN, Janssen Pharmaceuticals, BTG, Sirtex, Novartis, ROTOP, Bain Capital outside of the submitted work.JCz is a founder, board member, and holds equity in Sofie biosciences and Trethera Therapeutics. Intellectual property is patented by the University of California and licensed to Sofie Biosciences and Trethera Therapeutics. No other potential conflict of interest relevant to this article was reported.WF was a consultant for Endocyte and BTG, and he received fees from RadioMedix and Bayer outside of the submitted work.